Lupin Limited has informed the Exchange regarding a press release dated July 09, 2025, titled "Lupin and Zentiva Sign License and Supply Agreement for CommercializingCertolizumab".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin has signed a license and supply agreement with European pharma company Zentiva to commercialize its biosimilar Certolizumab Pegol across multiple global markets. Lupin will handle development, manufacturing, and supply, while Zentiva will manage commercialization in Europe and CIS markets (outside USA and Canada); Lupin will commercialize in the remaining regions including USA and Canada. Lupin will receive an upfront payment of USD 10 million plus up to USD 50 million in development and regulatory milestone payments. Profits from defined markets will be shared between the two companies, and both will co-invest in the biosimilar's development.
This is a positive development for Lupin shareholders — it expands global reach for a key biosimilar asset without bearing the full commercialization cost in Europe, provides near-term cash inflow (USD 10M upfront), and offers milestone-based upside up to USD 50M. Long-term profit sharing could boost revenue, though exact financial impact depends on market uptake.